Drug intelligence / Profile preview

MicrocynRX

Development stage: Phase 2
Lead developer: Sonoma Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

MicrocynRX is a topical antimicrobial wound care solution and hydrogel developed by Sonoma Pharmaceuticals. Its active ingredient is hypochlorous acid (HOCl), a small molecule produced through a proprietary electrochemical process. It is designed to treat various wound infections, including diabetic foot infections, by acting as a broad-spectrum disinfectant and antibacterial agent. Clinical data indicates it is safe, non-toxic, and comparable in efficacy to oral antibiotics like levofloxacin for mild diabetic foot infections. The product is formulated to be non-irritating and non-sensitizing, making it suitable for advanced wound care management.

Brand names: MicrocynRXMicrocyn RxMicrocyn
Other names: hypochlorous acidoxychlorine compound

Targets

Chitin

Beyond the preview

Go deeper on MicrocynRX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicrocynRX.

Explore the full profile